BR112017020131B1 - Composto, seu uso e composição farmacêutica - Google Patents

Composto, seu uso e composição farmacêutica Download PDF

Info

Publication number
BR112017020131B1
BR112017020131B1 BR112017020131-3A BR112017020131A BR112017020131B1 BR 112017020131 B1 BR112017020131 B1 BR 112017020131B1 BR 112017020131 A BR112017020131 A BR 112017020131A BR 112017020131 B1 BR112017020131 B1 BR 112017020131B1
Authority
BR
Brazil
Prior art keywords
methyl
morpholin
pyrazolo
pyrimidine
indol
Prior art date
Application number
BR112017020131-3A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112017020131A2 (pt
Inventor
Barbara DYMEK
Marcin ZAGOZDA
Maciej Wieczorek
Krzysztof DUBIEL
Aleksandra STANCZAK
Daria ZDZALIK
Pawel GUNERKA
Mariola SEKULAR
Maciej DZIACHAN
Original Assignee
Celon Pharma S.A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celon Pharma S.A filed Critical Celon Pharma S.A
Publication of BR112017020131A2 publication Critical patent/BR112017020131A2/pt
Publication of BR112017020131B1 publication Critical patent/BR112017020131B1/pt

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR112017020131-3A 2015-04-02 2016-03-30 Composto, seu uso e composição farmacêutica BR112017020131B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PL411864A PL236355B1 (pl) 2015-04-02 2015-04-02 Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
PL411864 2015-04-02
PCT/IB2016/051792 WO2016157091A1 (en) 2015-04-02 2016-03-30 7-(morpholin-4-yl)pyrazole[1,5-a]pyrimidine derivatives which are useful for the treatment of immune or inflammatory diseases or cancer

Publications (2)

Publication Number Publication Date
BR112017020131A2 BR112017020131A2 (pt) 2018-05-29
BR112017020131B1 true BR112017020131B1 (pt) 2023-02-28

Family

ID=55650626

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017020131-3A BR112017020131B1 (pt) 2015-04-02 2016-03-30 Composto, seu uso e composição farmacêutica

Country Status (18)

Country Link
US (1) US10138247B2 (https=)
EP (1) EP3277687B1 (https=)
JP (1) JP6665201B2 (https=)
KR (1) KR102559190B1 (https=)
CN (1) CN107743489B (https=)
AU (1) AU2016241568B2 (https=)
BR (1) BR112017020131B1 (https=)
CA (1) CA2978828A1 (https=)
DK (1) DK3277687T3 (https=)
EA (1) EA032826B1 (https=)
ES (1) ES2765642T3 (https=)
HR (1) HRP20192195T1 (https=)
HU (1) HUE047822T2 (https=)
MX (1) MX2017011423A (https=)
PL (2) PL236355B1 (https=)
PT (1) PT3277687T (https=)
SI (1) SI3277687T1 (https=)
WO (1) WO2016157091A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI885039B (zh) 2020-01-13 2025-06-01 美商邊際分析公司 經取代吡唑并嘧啶及其用途
WO2022064459A1 (en) * 2020-09-28 2022-03-31 1ST Biotherapeutics, Inc. Indazoles as hematopoietic progenitor kinase 1 (hpk1) inhibitors and methods of using same
US20240018151A1 (en) * 2020-10-19 2024-01-18 Tme Therapeutics Llc Novel inhibitors of pikfyve and methods using same
CN114957261B (zh) * 2022-05-17 2023-06-23 重庆文理学院 一种具有抗头颈癌作用的化合物及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU713673B2 (en) * 1996-02-07 1999-12-09 Neurocrine Biosciences Inc. Pyrazolopyrimidines as crf receptor antagonists
CN1918172B (zh) 2003-12-23 2011-09-14 活跃生物工艺学公司 利福霉素类似物及其用途
BRPI0607927A2 (pt) * 2005-02-11 2009-10-20 Hoffmann La Roche derivados de pirazol-pirimidina
HRP20100516T1 (hr) * 2006-09-20 2010-10-31 Eli Lilly And Company Tiazolpirazolopirimidini kao antagonisti receptora crf1
US20110230464A1 (en) 2007-10-26 2011-09-22 Paul Goldsmith Purine derivatives useful as p13 kinase inhibitors
MX2010009416A (es) 2008-02-26 2010-09-24 Novartis Ag Compuestos heterociclicos como inhibidores de cxcr2.
CA2721851A1 (en) * 2008-05-30 2009-12-03 Genentech, Inc. Purine pi3k inhibitor compounds and methods of use
WO2010037765A2 (en) * 2008-10-03 2010-04-08 Merck Serono S.A. 4-morpholino-pyrido[3,2-d]pyrimidines
JP5578490B2 (ja) * 2008-12-26 2014-08-27 味の素株式会社 ピラゾロピリミジン化合物
BRPI1014572B8 (pt) * 2009-04-16 2022-07-19 Fundacion Centro Nac De Investigaciones Oncologicas Carlos Iii Imidazopirazinas para uso como inibidores de cinase
BRPI1009022A2 (pt) 2009-05-27 2016-03-08 Hoffmann La Roche "composto, composição farmacêutica, processo para produzir uma composição farmacêutica, uso de um composto, método para tratamento de uma doença ou transtorno e kit"
US8158625B2 (en) * 2009-05-27 2012-04-17 Genentech, Inc. Bicyclic indole-pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use
GB0912745D0 (en) 2009-07-22 2009-08-26 Wolfson Microelectronics Plc Improvements relating to DC-DC converters
EP2539337A1 (en) 2010-02-22 2013-01-02 F. Hoffmann-La Roche AG Pyrido[3,2-d]pyrimidine pi3k delta inhibitor compounds and methods of use
US8969364B2 (en) 2010-03-04 2015-03-03 Merck Sharp & Dohme Corp. Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders
WO2013028263A1 (en) * 2011-08-24 2013-02-28 Glaxosmithkline Llc Pyrazolopyrimidine derivatives as pi3 kinase inhibitors

Also Published As

Publication number Publication date
BR112017020131A2 (pt) 2018-05-29
KR102559190B1 (ko) 2023-07-25
JP2018510192A (ja) 2018-04-12
ES2765642T3 (es) 2020-06-10
HUE047822T2 (hu) 2020-05-28
EP3277687B1 (en) 2019-10-30
CN107743489B (zh) 2021-05-04
EA032826B1 (ru) 2019-07-31
DK3277687T3 (da) 2019-12-16
PL411864A1 (pl) 2016-10-10
CN107743489A (zh) 2018-02-27
EP3277687A1 (en) 2018-02-07
EA201792087A1 (ru) 2018-03-30
JP6665201B2 (ja) 2020-03-13
MX2017011423A (es) 2018-05-17
SI3277687T1 (sl) 2020-02-28
PL236355B1 (pl) 2021-01-11
PL3277687T3 (pl) 2020-09-21
HRP20192195T1 (hr) 2020-03-06
PT3277687T (pt) 2020-01-10
US20180111939A1 (en) 2018-04-26
KR20170132275A (ko) 2017-12-01
CA2978828A1 (en) 2016-10-06
US10138247B2 (en) 2018-11-27
AU2016241568B2 (en) 2019-09-26
AU2016241568A1 (en) 2017-10-19
WO2016157091A1 (en) 2016-10-06

Similar Documents

Publication Publication Date Title
AU2021273566B2 (en) Imidazopyrrolopyridine as inhibitors of the JAK family of kinases
KR102280589B1 (ko) 바이러스 감염 또는 추가 질환의 치료를 위한 알킬피리미딘 유도체
JP6283320B2 (ja) ウイルス感染の治療のためのピペリジノ−ピリミジン誘導体
US10259814B2 (en) Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
CA2957046C (en) Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
JP6298998B2 (ja) ウイルス感染を治療するための１，２，４−トリアジン誘導体
WO2024183806A1 (en) Compounds, preparation methods and uses thereof
RU2569635C2 (ru) Замещенные пиридопиразины как новые ингибиторы syk
US10414769B2 (en) 5,8-dimethyl-9-phenyl-5,8-dihydro-6H-pyrazolo[3,4-h]quinazolin-2-yl)-(1H-pyrazol-3-yl)-amines as IGF-1R/IR inhibitors
US20140249164A1 (en) Compounds
WO2009122180A1 (en) Pyrimidine derivatives capable of inhibiting one or more kinases
WO2018045956A1 (zh) 苯并咪唑类化合物激酶抑制剂及其制备方法和应用
JP2019509272A (ja) 脊髄性筋萎縮症の治療のための併用療法
BR112017020131B1 (pt) Composto, seu uso e composição farmacêutica
JP6858252B2 (ja) ラパマイシンシグナル伝達経路阻害剤のメカニズム標的、及びその治療応用
JP2025500871A (ja) ピリミジン又はピリジン誘導体及びその医薬用途
US20230303562A1 (en) Pyrazole compound and preparation method therefor and use thereof
WO2025149623A1 (en) Wnk1 inhibitors
CN116239597A (zh) 一种嘧啶并吡咯类衍生物及其药用组合物和应用
HK40042846B (zh) Fgfr4抑制剂及其应用

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/03/2016, OBSERVADAS AS CONDICOES LEGAIS

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 9A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2822 DE 04-02-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.